Search results for "Intravenou"

showing 10 items of 390 documents

Nonlinearities in amoxycillin pharmacokinetics. I. Disposition studies in the rat.

1992

Several features of amoxycillin pharmacokinetics in man are not well known in spite of the extensive clinical use of the antibiotic. In this paper it is demonstrated that amoxycillin disposition kinetics in rats is clearly nonlinear, and that this may be due mainly to its elimination mechanisms. At different intravenous bolus dose levels, and in steady-state perfusion studies, the most striking feature is an increased renal clearance as dose increases (from 3.5 to 7.0 mg kg-1 for intravenous bolus, and from 4.6 to 20.0 micrograms min-1 for intravenous perfusions). This phenomenon has been attributed to a saturation of the active renal tubular reabsorption of the antibiotic. When the intrave…

Malemedicine.medical_specialtymedicine.drug_classAntibioticsPharmaceutical SciencePharmacologyModels BiologicalBolus (medicine)PharmacokineticsInternal medicinemedicineAnimalsPharmacology (medical)PharmacologyIntravenous dosePlasma clearanceAnalysis of VarianceChemistryAmoxicillinRats Inbred StrainsGeneral MedicineDispositionRatsEndocrinologyPerfusionTubular secretionBiopharmaceuticsdrug disposition
researchProduct

Dose-dependent metabolism and hepatic distribution of phenprocoumon in rats

1988

The dose-dependency of phenprocoumon disposition was determined in rats by iv administration of 0.1 and 1.0 mg/kg doses to separate groups of animals. The intrinsic clearance (unbound clearance) was 33% lower in the animals given 1.0 mg/kg dose than in the animals given 0.1 mg/kg dose. The apparent unbound volume of distribution was 55% lower and the elimination rate constant 54% higher in the high dose group than in the lower dose group. Binding of phenprocoumon to liver showed saturability with a two- to threefold higher apparent unbound fraction of phenprocoumon in liver in animals given the high dose in comparison to animals given the low dose.

Malemedicine.medical_specialtymedicine.drug_classDose dependencePhenprocoumonPharmacokineticsElimination rate constantInternal medicinemedicineAnimalsDistribution (pharmacology)Tissue DistributionPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsVolume of distributionDose-Response Relationship DrugChemistryAnticoagulantRats Inbred Strains4-HydroxycoumarinsMetabolismRatsEndocrinologyLiverInjections IntravenousPhenprocoumonCarrier Proteinsmedicine.drugJournal of Pharmacokinetics and Biopharmaceutics
researchProduct

Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart …

2014

The use of loop diuretics in acute heart failure (AHF) is largely empirical and has been associated with renal function impairment by reducing renal perfusion but also renal improvement by decreasing renal venous congestion. Antigen carbohydrate 125 (CA125) has emerged as a proxy for fluid overload. We sought to evaluate whether the early changes in creatinine (ΔCr) induced by intravenous furosemide doses (ivFD) differ among clinical groups defined by overload status (CA125) and creatinine on admission (Cr).We included 526 consecutive patients admitted for AHF. All patients received intravenous furosemide for the first 48 hours. CA125 and Cr were dichotomized at 35 U/ml and 1.4 mg/dl, respe…

Malemedicine.medical_specialtymedicine.drug_classUrologyRenal functionKidneyCohort Studieschemistry.chemical_compoundPatient AdmissionAntigenSodium Potassium Chloride Symporter InhibitorsPredictive Value of TestsInternal medicinemedicineHumansIn patientInfusions IntravenousAgedAged 80 and overHeart FailureCreatininebusiness.industryFurosemideCarbohydrateLoop diureticMiddle Agedmedicine.diseaseEndocrinologychemistryHeart failureCA-125 AntigenCreatinineAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

Differences in the composition of inflammatory cell infiltrate in lens-induced uveitis under therapy with allopurinol or steroids.

2001

Purpose The aim of this study was to compare the qualitative changes in the composition of inflammatory cell infiltrate in lens-induced uveitis (LIU) under treatment with allopurinol (Allo), methylprednisolone (Pred) or the two drugs combined (Allo/Pred). Methods Twenty male Wistar rats were sensitized with lens proteins for eight weeks. Intravenous (IV) therapy was started after anterior capsule disruption in one eye of each animal. Five rats were randomly assigned to each of the four groups: controls, Allo (50 mg/kg bw), Pred (7.5 mg/kg bw) and Allo/Pred (50 mg/7.5 mg per kg bw). Eyes were enucleated 24 hours later and fixed in paraformaldehyde/glutaraldehyde. Sections at three levels wer…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAllopurinolAllopurinolMethylprednisoloneGiemsa stainLens proteinUveitis03 medical and health scienceschemistry.chemical_compoundLeukocyte Count0302 clinical medicineInternal medicinemedicineLeukocytesAnimalsRats WistarParaformaldehydeGlucocorticoidsChemotherapybusiness.industryGeneral MedicineFree Radical Scavengersmedicine.diseaseCrystallinsRatsOphthalmologyDisease Models AnimalEndocrinologychemistryMethylprednisoloneInjections Intravenous030221 ophthalmology & optometryCorticosteroidDrug Therapy Combinationbusiness030217 neurology & neurosurgeryUveitismedicine.drugEuropean journal of ophthalmology
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refract…

2003

Background Diuretics have been accepted as first-line treatment in refractory congestive heart failure (CHF), but a lack of response to them is a frequent event. A randomized, single-blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory New York Heart Association (NYHA) class IV CHF and a normosodic diet during follow-up. Materials and Methods One hundred seven patients (39 women and 68 men, age range 65-90 years) with refractory CHF (NYHA class IV) of different etiologies, who were unresponsive to high oral doses of furosemide, angiotensin-converting enzyme inhib…

Malemedicine.medical_specialtymedicine.medical_treatmentAdministration OralDrug Administration ScheduleBolus (medicine)FurosemideHeart rateMedicineHumansSingle-Blind MethodDiureticsInfusions IntravenousBlood urea nitrogenAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionDose-Response Relationship Drugbusiness.industryFurosemideSodium Dietarymedicine.diseaseSurvival AnalysisSurgeryTreatment OutcomeHeart failureAnesthesiaQuality of LifeFemaleDiureticCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.

1994

A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolusvs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 …

Malemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchGastroenterologyBolus (medicine)Hepatic arterial infusionHepatic ArteryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialInfusions IntravenousSurvival rateCisplatinChemotherapybusiness.industryLiver NeoplasmsGastroenterologyGeneral MedicineMiddle AgedSurvival RateInjections Intra-ArterialFluorouracilAnesthesiaToxicityFemaleFluorouracilCisplatinbusinessColorectal Neoplasmsmedicine.drugDiseases of the colon and rectum
researchProduct

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021

Abstract Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% o…

Malemedicine.medical_specialtyustekinumabVedolizumab03 medical and health sciences0302 clinical medicineremissionColitis ulcerosaInternal medicineUstekinumabHumansMedicineProspective StudiesRegistriesInfusions IntravenousAdverse effectreal-world evidenceAcademicSubjects/MED00260ulcerative colitisTofacitinibresponsebiologybusiness.industryRemission InductionC-reactive proteinGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuation030220 oncology & carcinogenesisCohortbiology.proteindurabilityOriginal ArticleColitis UlcerativeFemaleMonoclonal antibodies030211 gastroenterology & hepatologyUstekinumabbusinessAnticossos monoclonalsmedicine.drug
researchProduct

Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke

2016

Background and Purpose— We compared outcome and complications in patients with stroke treated with intravenous thrombolysis (IVT) who could not live alone without help of another person before stroke (dependent patients) versus independent ones. Methods— In a multicenter IVT-register–based cohort study, we compared previously dependent (prestroke modified Rankin Scale score, 3–5) versus independent (prestroke modified Rankin Scale score, 0–2) patients. Outcome measures were poor 3-month outcome (not reaching at least prestroke modified Rankin Scale [dependent patients]; modified Rankin Scale score of 3–6 [independent patients]), death, and symptomatic intracranial hemorrhage. Unadjusted an…

Malemedicine.medical_treatment030204 cardiovascular system & hematologylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawModified Rankin ScaleActivities of Daily Living80 and overThrombolytic TherapyRegistriesStrokeriskAged 80 and overpreexisting disabilityMedicine (all)survivorsThrombolysisMiddle Aged3. Good healthStrokeTreatment OutcomeInfusions intravenous; Intracranial hemorrhages; Outcome assessment (health care); Stroke; Survivors; Administration Intravenous; Aged; Aged 80 and over; Cohort Studies; Female; Humans; Logistic Models; Male; Middle Aged; Stroke; Treatment Outcome; Activities of Daily Living; Independent Living; Registries; Thrombolytic Therapy; Medicine (all); Neurology (clinical); Cardiology and Cardiovascular Medicine; Advanced and Specialized Nursingcontrolled-trialAdministration[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Administration IntravenousFemaleIndependent Livingacute ischemic-strokehemorrhageCardiology and Cardiovascular MedicineCohort studymedicine.medical_specialtyintracranial hemorrhagesstatinsscale03 medical and health sciencesInternal medicinemedicineHumansDementiaAgedoutcome assessment (health care)Advanced and Specialized Nursingreliabilitybusiness.industryOdds ratiomedicine.diseaseConfidence intervalinfusionsSurgeryLogistic Models[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]intravenousiv thrombolysisNeurology (clinical)business030217 neurology & neurosurgeryStroke
researchProduct

The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.

2017

Background The presence of an intracranial aneurysm is contraindicated to recombinant tissue plasminogen activator (r-tPA) treatment for acute ischemic stroke. However, it is difficult to exclude asymptomatic intracranial aneurysms by using conventional, noncontrast head computed tomography (CT), which is the only neuroimaging suggested before r-tPA. Recent case reports and series have shown that administering r-tPA to patients with a pre-existing aneurysm does not increase the bleeding risk. However, Asians are known to have a relatively higher bleeding risk, and little evidence is available regarding the risk of using r-tPA on Asian patients with intracranial aneurysms. Methods Medical re…

Malemedicine.medical_treatmentlcsh:MedicineCardiovascular Medicine030204 cardiovascular system & hematologyPathology and Laboratory MedicineVascular MedicineMagnetic resonance angiographyDiagnostic Radiology0302 clinical medicineRisk FactorsMedicine and Health SciencesMedicineThrombolytic TherapyCardiovascular ImagingInfusions Intravenouslcsh:ScienceTomographyStrokeAged 80 and overMultidisciplinarymedicine.diagnostic_testRadiology and ImagingMedical recordAngiographyArteriesThrombolysisStrokeHemorrhagic StrokeNeurologyTissue Plasminogen Activatorcardiovascular systemFemaleRadiologyAnatomymedicine.symptomAneurysmsIntracranial HemorrhagesResearch Articlemedicine.medical_specialtyImaging TechniquesCerebrovascular DiseasesTaiwanHemorrhageNeuroimagingResearch and Analysis MethodsAsymptomatic03 medical and health sciencesSigns and SymptomsAneurysmDiagnostic MedicineHumansVascular Diseasescardiovascular diseasesIschemic StrokeAgedbusiness.industrylcsh:RBiology and Life SciencesIntracranial AneurysmMagnetic resonance imagingCerebral Arteriesmedicine.diseaseComputed Axial TomographyAngiographyCardiovascular AnatomyBlood Vesselslcsh:QbusinessMagnetic Resonance Angiography030217 neurology & neurosurgeryNeurosciencePLoS ONE
researchProduct

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

2018

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves' orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

Malemusculoskeletal diseasesDecompressionmedicine.medical_specialtyDecompressionmedicine.medical_treatmentVisual Acuity030209 endocrinology & metabolismdysthyroid optic neuropathyAntibodies Monoclonal HumanizedOptic neuropathy03 medical and health scienceschemistry.chemical_compoundGraves' orbitopathytocilizumab0302 clinical medicineTocilizumabRefractoryOptic Nerve DiseasesmedicineHumansbusiness.industryTreatment optionsMiddle Agedmedicine.diseaseeye diseasesSurgeryRadiation therapyGraves OphthalmopathyOphthalmologychemistry030221 ophthalmology & optometryPrimary treatmentVisual FieldsIntravenous steroidsbusinessTomography Optical Coherencesteroids
researchProduct